EUTOS score predicts survival and cytogenetic response in patients with chronic phase chronic myeloid leukemia treated with first-line imatinib

被引：15
|
作者：
Tao, Zhonfei [1 ,2 ,3 ,5 ]
Liu, Bingcheng [1 ,2 ,3 ]
Zhao, Yaozhong [1 ,2 ,3 ]
Wang, Ying [1 ,2 ,3 ]
Zhang, Rongli [1 ,2 ,3 ]
Han, Mingzhe [1 ,2 ,3 ]
Zhang, Li [1 ,2 ,3 ]
Li, Chengwen [2 ,3 ,4 ]
Ru, Kun [2 ,3 ,4 ]
Mi, Yingchang [1 ,2 ,3 ]
Wang, Jianxiang [1 ,2 ,3 ,5 ]
机构：
[1] Chinese Acad Med Sci, Dept Clin Hematol, Inst Hematol, Tianjin 300020, Peoples R China
[2] Chinese Acad Med Sci, Blood Dis Hosp, Tianjin 300020, Peoples R China
[3] Peking Union Med Coll, Tianjin 300020, Peoples R China
[4] Chinese Acad Med Sci, Dept Hemopathol, Inst Hematol, Tianjin 300020, Peoples R China
[5] Chinese Acad Med Sci, State Key Lab Expt Hematol, Inst Hematol, Tianjin 300020, Peoples R China
来源：
LEUKEMIA RESEARCH | 2014年 / 38卷 / 09期
基金：
中国国家自然科学基金;
关键词：
EUTOS; Chronic myeloid leukemia; Complete cytogenetic response; Overall survival; Progression free survival; Prognosis; PATIENTS RECEIVING IMATINIB; TYROSINE KINASE INHIBITORS; EUROPEAN TREATMENT; PROGNOSTIC SCORE; FOLLOW-UP; CML; FRONTLINE; RECOMMENDATIONS; RESISTANCE; THERAPY;
D O I：
10.1016/j.leukres.2014.06.006
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Sokal, Euro and newly developed EUTOS scoring systems were validated in 220 Chinese chronic phase chronic myeloid leukemia (CP-CML) patients treated with frontline imatinib. In the EUTOS low-risk and high-risk groups, the 5-year OS was 98.7% vs. 71.4% (P<0.0001), and the 5-year cumulative incidence of complete cytogenetic response (CCyR) was 92.4% vs. 53.8% (p<0.0001). EUTOS score also predicted progression-free survival and duration of CCyR. Low EUTOS index predicted for CCyR. However, Sokal and Euro scores mainly could not discriminate the intermediate-risk from high-risk group in either survival or CCyR. EUTOS score forecasts the prognosis of CP-CML patients treated with first-line imatinib. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码：1030 / 1035
页数：6
相关论文
共 50 条
  • [1] Performance of Sokal and Eutos Scores for Predicting Cytogenetic and Molecular Response in Newly Diagnosed Chronic Myeloid Leukemia-Chronic Phase Patients on Imatinib
    Ganguly, Sandip
    Lakshmaiah, K. C.
    Jacob, Linu Abraham
    Babu, Suresh
    Dasappa, Lokanatha
    Babu, K. S. Govind
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2017, 33 (01) : 82 - 86
  • [2] Moderate anemia at diagnosis is an independent prognostic marker of the EUTOS, Sokal, and Hasford scores for survival and treatment response in chronic-phase, chronic myeloid leukemia patients with frontline imatinib
    Ko, Po-Shen
    Yu, Yuan-Bin
    Liu, Yao-Chung
    Wu, Yi-Tsui
    Hung, Man-Hsin
    Gau, Jyh-Pyng
    Liu, Chia-Jen
    Hsiao, Liang-Tsai
    Chena, Po-Min
    Chiou, Tzeon-Jye
    Liu, Chun-Yu
    Liu, Jin-Hwang
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (10) : 1737 - 1744
  • [3] EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia
    Tiribelli, Mario
    Bonifacio, Massimiliano
    Calistri, Elisabetta
    Binotto, Gianni
    Maino, Elena
    Marin, Luciana
    Guardalben, Emanuele
    Branca, Antonio
    Gherlinzoni, Filippo
    Semenzato, Gianpietro
    Sancetta, Rosaria
    Pizzolo, Giovanni
    Fanin, Renato
    LEUKEMIA RESEARCH, 2013, 37 (11) : 1457 - 1460
  • [4] Validation of the EUTOS Long-Term Survival Score in Chinese Chronic Myeloid Leukemia Patients Treated with Imatinib: A Multicenter Real-World Study
    Yang, Xiawan
    Bai, Yanliang
    Shi, Mingyue
    Zhang, Wanjun
    Niu, Junwei
    Wu, Chengye
    Zhang, Lei
    Xu, Zhiwei
    Liu, Xiang
    Chen, Yuqing
    Sun, Kai
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 1293 - 1301
  • [5] Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase
    Quintas-Cardama, Alfonso
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    CANCER, 2011, 117 (23) : 5261 - 5270
  • [6] Performance of Sokal and Eutos Scores for Predicting Cytogenetic and Molecular Response in Newly Diagnosed Chronic Myeloid Leukemia-Chronic Phase Patients on Imatinib
    Sandip Ganguly
    K. C. Lakshmaiah
    Linu Abraham Jacob
    Suresh Babu
    Lokanatha Dasappa
    K. S. Govind Babu
    Indian Journal of Hematology and Blood Transfusion, 2017, 33 : 82 - 86
  • [7] EUTOS Long-Term Survival Score in Peruvian Chronic Myeloid Leukemia Patients Treated with Imatinib: A Real-World Experience
    Untama, Jose
    Pizarro, Marlies
    Huaman, Veronica
    Carbone, Ethan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S383 - S383
  • [8] Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia
    Gugliotta, Gabriele
    Castagnetti, Fausto
    Breccia, Massimo
    Gozzini, Antonella
    Usala, Emilio
    Carella, Angelo M.
    Rege-Cambrin, Giovanna
    Martino, Bruno
    Abruzzese, Elisabetta
    Albano, Francesco
    Stagno, Fabio
    Luciano, Luigia
    D'Adda, Mariella
    Bocchia, Monica
    Cavazzini, Francesco
    Tiribelli, Mario
    Lunghi, Monia
    Falcone, Antonietta Pia
    Musolino, Caterina
    Levato, Luciano
    Venturi, Claudia
    Soverini, Simona
    Cavo, Michele
    Alimena, Giuliana
    Pane, Fabrizio
    Martinelli, Giovanni
    Saglio, Giuseppe
    Rosti, Gianantonio
    Baccarani, Michele
    AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (06) : 617 - 622
  • [9] Considerations for early switch to nilotinib or dasatinib in patients with chronic myeloid leukemia with inadequate response to first-line imatinib
    Quintas-Cardama, Alfonso
    Jabbour, Elias J.
    LEUKEMIA RESEARCH, 2013, 37 (05) : 487 - 495
  • [10] Feasibility Study of Switching to Nilotinib After First-line Imatinib in the Chronic Phase of Chronic Myeloid Leukemia
    Chen, Yilin
    Yin, Hua
    Chen, Lifeng
    Xiong, Yingyuan
    Meng, Li
    Guo, Jingming
    Wang, Haiyan
    Li, Weiming
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (02) : E43 - E49
12345